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Summary
Inflammatory bowel disease (IBD) is characterized by a
chronic relapsing intestinal inflammation. IBD is sub-
divided into Crohn disease and ulcerative colitis phe-
notypes. Given the immunologic dysregulation in IBD,
the human-leukocyte-antigen region on chromosome 6p
is of significant interest. Previous association and linkage
analysis has provided conflicting evidence as to the ex-
istence of an IBD-susceptibility locus in this region. Here
we report on a two-stage linkage and association anal-
ysis of both a basic population of 353 affected sibling
pairs (ASPs) and an extension of this population to 428
white ASPs of northern European extraction. Twenty-
eight microsatellite markers on chromosome 6 were gen-
otyped. A peak multipoint LOD score of 4.2 was ob-
served, at D6S461, for the IBD phenotype. A transmis-
sion/disequilibrium test (TDT) result of wasP = .006
detected for D6S426 in the basic population and was
confirmed in the extended cohort ( ; 97 vs. 56P = .004
transmissions). The subphenotypes of Crohn disease, ul-
cerative colitis, and mixed IBD contributed equally to
this linkage, suggesting a general role for the chromo-
some 6 locus in IBD. Analysis of five single-nucleotide
polymorphisms in the TNFA and LTA genes did not
reveal evidence for association of these important can-
didate genes with IBD. In summary, we provide firm
linkage evidence for an IBD-susceptibility locus on chro-
mosome 6p and demonstrate that TNFA and LTA are
unlikely to be susceptibility loci for IBD.
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Introduction
Inflammatory bowel disease (IBD [MIM 601458, MIM
266600, and MIM 191390]) is clinically characterized
by abdominal pain, chronic diarrhea, rectal bleeding,
weight loss, intestinal stenoses, fistulas, toxic megacolon,
and such associated extraintestinal manifestations as ar-
thritis and uveitis (Podolsky 1991). It affects ∼1/1,000
individuals in Western countries, with the median age
at onset being during early adulthood (Probert et al.
1996; Shivananda et al. 1996). The etiology of this dis-
order is unknown. The pathophysiology is characterized
by a chronic relapsing inflammation of the gastrointes-
tinal tract. On the basis of clinical and histopathologic
features, IBD is categorized into two main subtypes:
Crohn disease (CD [MIM 266600]) and ulcerative colitis
(UC [MIM 191390]) (Hamilton 1987; Podolsky 1991).
Chromosome 6 has been implicated in the etiology of
IBD, by association and genetic-linkage studies dating
as far back as 1972. Previously reported associations
include class I (Gleeson et al. 1972; van den Berg-Loonen
et al. 1977; Purrmann et al. 1985; Biemond et al. 1986),
class II (Fujita et al. 1984; Toyoda et al. 1993; Nakajima
et al. 1995), and tumor necrosis factor–a (TNF-a) alleles
(Bouma et al. 1996; Plevy et al. 1996). However, the
association data for human leukocyte antigen (HLA) and
TNF-a are not conclusive (Russell et al. 1975; Delpre
et al. 1980; Smolen et al. 1982; Satsangi et al. 1996b).
Recent association studies have suggested a role for HLA
in susceptibility to UC (Roussomoustakaki et al. 1997;
Perri et al. 1998; Uyar et al. 1998; Bouma et al. 1999)
and CD (Forcione et al. 1996). Neither the particular
HLA antigen that might confer susceptibility to IBD nor
the particular subphenotype that might be affected is
clear.
TNF-a is a key inflammatory mediator in the path-
ophysiology of IBD. The ex vivo capacity of lamina pro-
pria mononuclear cells to produce TNF-a has been used
to predict relapse in CD (Schreiber et al. 1999). Fur-
thermore, therapeutic interventions targeting TNF-a
with a monoclonal antibody have proved to be effective
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Table 1
Number of Sibships and ASPs in Both the Family Cohort Used in the Basic Study and the Extended Cohort
NO. OF SIBSHIPS/(ASPSa) IN EACH COHORT STUDIED, ACCORDING TO DISEASE TYPE
Basic Cohort Extended Cohort
SIBSHIP SIZE CD UC Mixedb Total CD UC Mixedb Total
2 114 (114) 78 (78) 38 (38) 230 (230) 150 (150) 102 (102) 47 (47) 299 (299)
3 14 (42) 12 (36) 9 (27) 35 (105) 14 (42) 13 (39) 10 (30) 37 (111)
4 1 (6) 2 (12) 3 (18) 1 (6) 2 (12) 3 (18)
Total 129 (162) 90 (114) 49 (77) 268 (353) 165 (198) 115 (141) 59 (89) 339 (428)
NOTE.—Both parents were available for analysis in 55% of the 339 families.
a Ordered according to sibship size and disease type within the family.
b Mixed = sibships with both CD and UC.
in clinical trials (Targan et al. 1997). Given these data,
the question of whether TNF-a gene variations are an
etiologic factor in IBD is intriguing. Association of an
inferred haplotype (TNFa2b1c2d4e1) of microsatellites
flanking the TNF locus with CD has been described
(Plevy et al. 1996) in 148 patients with IBD and in 60
control subjects, yielding P values of .01 (odds ratio
[OR] 4.4) and .001 (OR 7.4) in comparison with those
for control subjects and patients with UC, respectively.
In a direct investigation of polymorphisms of the TNFA-
gene promoter and two RFLPs of the lymphotoxin-a
(LTA) gene in 154 patients with IBD and in 54 healthy
control subjects, the uncommon allele 2 of the 308
TNFA promoter polymorphism was found to be de-
creased in UC ( ) (Bouma et al. 1996). FurtherP = .044
investigation involving the use of both the microsatellites
and the known functional single-nucleotide polymor-
phisms of this region is therefore warranted.
Despite the several positive association findings in this
genomic region and despite the strong functional evi-
dence supporting TNF-a, questions remain regarding (1)
the existence and relevance of an IBD risk factor on
chromosome 6 and (2) the putative genetic role of TNF
in the etiology of IBD. This uncertainty stems, in part,
from the lack of linkage evidence fulfilling the signifi-
cance criterion of a LOD score 13.6, as defined by
Lander and Krugylak (1995). Several groups have re-
ported suggestive evidence for linkage of IBD to chro-
mosome 6p. In our previous genomewide linkage anal-
ysis, a LOD score of 2.1 was observed (Hampe et al.
1999). Yang et al. (1999) have also reported evidence
supporting a role for the chromosome 6p region, with
the use of multiple regression analysis in 49 families with
CD. Other previous genomewide linkage analyses, by
Hugot et al. (1994) and by Satsangi et al. (1996a), did
not indicate the actual significance levels attained for
chromosome 6 markers, since no significant LOD score
13.6 was observed. In the recent genomewide analysis
by Cho et al. (1998), a multipoint LOD score of 0.7 was
observed for chromosome 6p. Satsangi et al. (1996b)
have also reported a P value of .017 for linkage of UC
to the DRB1 locus.
Given our prior suggestive linkage results for the HLA
region (Hampe et al. 1999), which were obtained by
genomewide analysis, we hypothesized that this region
may harbor a gene predisposing to IBD. To test this
hypothesis, we increased the marker density in this re-
gion by adding an additional 11 microsatellite markers
and by expanding the study population to a total of 428
ASPs. In view of the previous functional and genetic
evidence implicating TNF-a, we tested five known func-
tional single-nucleotide polymorphisms in the TNFA and
LTA genes in the expanded population.
Families and Methods
Family Ascertainment and Phenotypes
A family cohort recruited by an international group
of IBD investigators at the Charite University Hospital,
Berlin; the I Department of Medicine at the Christian-
Albrechts-University Kiel, Kiel, Germany; King’s College
School of Medicine, Guy’s Hospital, and St. Mark’s
Hospital, London; Academic Medical Center, Amster-
dam; and other central European centers was investi-
gated in this study. Forty-six percent of the families were
of German origin, 6% were from the Netherlands, and
48% were recruited in the United Kingdom. Informed,
written consent was obtained from all study partici-
pants. Recruitment protocols were approved by insti-
tutional review committees at each participating center.
Diagnosis of IBD and classification as CD or UC were
determined by the use of standard diagnostic criteria, as
described elsewhere (Truelove and Pena 1976; Lennard-
Jones 1989). The basic cohort has been used in previous
studies within the collaborative group (Curran et al.
1998; Hampe et al. 1998, 1999; Olavesen et al., in
press). Ascertainment criteria were determined prior to
the initiation of patient collection. It was required that
clinical, radiological, and endoscopic (type and distri-
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Table 2
Overview of Oligonucleotides Used for TAQman Assays Detecting Polymorphisms in TNF Genes
Polymorphism
and Type of
Probe or Primer Oligonucleotidesa
Concentration
(nM)
PCR
Conditions
TNF-b:
NcoI:
Forward
Reverse
Probe 1
Probe 2
GGGCCTTGGTGGGTTTGGTT
AAGGGGACAAGATGCAGTCAGAGAA
Fam-TCTGTTTCTGCCATGATTCCTCTCTGTTCC-Tamra
Tet-CTGTTTCTGCCATGGTTCCTCTCTGTTCC-Tamra
900
900
200
200
50 cycles at
65C annealing and
1-min extension
Asn26:
Forward
Reverse
Probe 1
Probe 2
CCCGTCAGCACCCCAAGATG
TGGGAGGTCAGGTGGATGTTTACC
Fam-TTGCCCACAGCACCCTCAAACCTG-Tamra
Tet-TGCCCACAGCAACCTCAAACCTGC-Tamra
900
900
100
100
40 cycles at
65C annealing and
1-min extension
TNF-a:
308:
Forward
Reverse
Probe 1
Probe 2
CCTGCATCCTGTCTGGAAGTTAGAAG
TGGGCCACTGACTGATTTGTGTGT
Fam-AACCCCGTCCCCATGCCCCTC-Tamra
Tet-AACCCCGTCCTCATGCCCCTCAA-Tamra
1,000
1,000
100
100
45 cycles at
70C annealing and
1-min extension
244:
Forward
Reverse
Probe 1
Probe 2
CCTCCAGGGTCCTACACACA
ACAAGCATCAAGGATACCCCTC
Fam-CCCAGAAGACCCCCCTCAGAATC-Tamra
Tet-CCAGAAGACCCCCCTCGGAATC-Tamra
900
900
100
100
40 cycles at
60C annealing and
30-s extension
238:
Forward
Reverse
Probe 1
Probe 2
CAGTGGCCCAGAAGACCC
AGCATCAAGGATACCCCTCAC
Fam-AATCGGAGCAGGGAGGATGGG-Tamra
Tet-AATCAGAGCAGGGAGGATGGGGA-Tamra
900
300
100
100
40 cycles at
60C annealing and
30-s extension
NOTE.—The polymorphisms and their sequences were retrieved from the literature (Messer et al. 1991; Ferencik et al. 1992;
Weissensteiner and Lanchbury 1997).
a The polymorphic nucleotide is underlined.
bution of lesions) examinations unequivocally confirm
the diagnosis of either UC or CD. Histology findings
had to either confirm or be compatible with this diag-
nosis. In instances of uncertainty, the diagnosis of in-
determinate colitis was assigned, and the patient was
excluded from the study. For families originating in the
United Kingdom and the Netherlands, medical records
for all patients were reviewed by one or more of the
principal investigators. For families of German origin,
patients were directly examined by one or more of the
principal investigators, when possible. Alternatively, two
written records containing a detailed disease history and
the results of all diagnostic procedures were obtained
for each patient and were reviewed by the principal in-
vestigators. A venous blood sample was obtained from
the affected siblings and their parents, if possible. An
overview of the family cohort is given in table 1.
Genotyping
Genomic DNA was prepared from whole blood by
use of the Puregene system (Gentra Systems). Twenty-
eight highly polymorphic microsatellite markers on
chromosome 6 were genotyped by fluorescent methods,
as described by Hall and Nanthakumar (1997). Primer
sequences were derived from The Genome Database or
from the literature (Partanen and Koskimes 1988). In
brief, individual DNA samples were arrayed in 96-well
microtiter plates and were amplified by PCR with the
appropriate primers. Product length of the microsatellite
markers was determined, on denaturing polyacrylamide
gels, by electrophoresis done with the use of ABI 377
automated DNA sequencers. Allele analyses and indi-
vidual allele calling were performed as described else-
where (Hall and Nanthakumar 1997; Idury and Cardon
1997).
Single-nucleotide polymorphisms in the TNF genes
were typed with the use of TAQman technology from
PE Biosystems. This method uses the 5′-exonuclease ac-
tivity of the Taq polymerase in a combination of PCR
and competitive hybridization (Holland et al. 1991; Li-
vak et al. 1995). Probes and primers were designed with
the use of Primer Express software (PE Biosystems). Oli-
gonucleotides and reaction conditions are given in table
2. A map indicating marker positions in the TNF gene
1650 Am. J. Hum. Genet. 65:1647–1655, 1999
Figure 2 Multipoint MLS curves for chromosome 6 from the
basic family data set. Multipoint analyses were performed with use
of the MAPMAKER/SIBS program. Results for CD (dashed line),
UC (thin unbroken line), and ALL (thick unbroken line) are shown.
Genetic distances between markers were estimated from the data set.
Marker positions are denoted by blackened diamonds.
Figure 1 Overview of TNF region: relative positions of the
TNF microsatellites a–e and of the single-nucleotide polymorphisms
of the TNFA and LTA genes and their promoters (top). The physical
distances are approximate. Distances in the top panel are derived
from GenBank record Y14768. The linkage map of the wider area
(bottom) shows genetic map distances, as derived from the analyzed
data set.
region is given in figure 1. PCR reactions were performed
in an ABI 9700, and fluorescence results were deter-
mined with the use of an ABI 7700 sequence-detector
single-point measurement. Genotype errors resulting
from non-Mendelian segregation in pedigrees were de-
tected and corrected as described by Hall and Nanthak-
umar (1997).
To facilitate inclusion of markers from different ge-
netic maps (e.g., Centre d’Etude du Polymorphisme Hu-
main and Cooperative Human Linkage Center), marker
order and distances were calculated with the use of ge-
notype data from the 339 pedigrees. The genetic map
was constructed by use of the automated mapping pro-
gram MultiMap, version 2.0 (Matise et al. 1994).
Statistical Analysis
Genetic analyses were conducted with the use of the
two aforementioned standard diagnostic categories: CD
and UC. A third category, ALL, contains CD/CD, UC/
UC, and CD/UC (mixed) ASPs. The ALL category there-
fore represents IBD as a single phenotype for analysis.
Allele frequencies for each marker were calculated from
the cohort genotype data for all individuals. Each
marker was analyzed in ASPs, by means of both two-
point and multipoint nonparametric allele-sharing tests,
with the use of MAPMAKER/SIBS with the “weighted
pairs” option (Kruglyak and Lander 1995). For multi-
point analysis, LOD scores were computed at 1-cM in-
tervals along the chromosome. The mean information
content across chromosome 6p was 85%.
Association statistics were calculated by the TDTLIKE
program from the ANALYZE software package (Ter-
williger 1995). Tested alleles are restricted to 10 ob-
served transmissions. The program algorithm provides
P values corrected for the testing of multiple alleles.
Results
Previous analyses involving the use of 17 micro-
satellite markers in the basic cohort of 353 ASPs re-
vealed suggestive evidence of linkage in the HLA re-
gion on chromosome 6p. A peak LOD score of 2.1
was observed close to marker D6S276 (Hampe et al.
1999). To further investigate this interval, 11 addi-
tional microsatellites in the peak region between
D6S309 and D6S257 were analyzed. The multipoint
maximum-likelihood-score (MLS) curves for UC, CD,
and the combined, ALL phenotype are shown in figure
2. For the IBD phenotype, the maximum MLS of 2.9
is located !1 cM from D6S461. The complete two-
point results for all analyzed markers are shown in
table 3. In the total IBD population, a maximum two-
point LOD score of 2.12 was observed for the TNFa
microsatellite marker, and, in the UC subpopulation,
a LOD score of 2.27 was seen at D6S461. The sub-
phenotypes of CD and UC and the mixed populations
(which show UC and CD in the same family) con-
tribute approximately equally to the linkage results.
When 11 markers were added in this linkage region,
the maximum information content increased from 80%
to 95%. Genotyping of further markers was therefore
not expected to improve the linkage information or the
magnitude of linkage results. To increase power to detect
linkage, the study cohort was expanded to 428 ASPs.
Five microsatellite markers covering 10 cM of the peak
linkage, as well as five flanking markers, were genotyped
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Table 3
Two-Point LOD Scores and TDT Results for Loci in Chromosome 6 Linkage Region
RESULTS FOR LOCI IN THE CHROMOSOME 6 REGION
OF TWO STUDY POPULATIONS
Basic Population Extended Population
Two-Point
LOD Scorea
Two-Point
LOD Scorea
LOCUS THETA CD UC ALL TDTb (P Value) CD UC ALL TDTb (P Value)
D6S309 .014 .49 .28 .72 1.05
D6S470 .101 .18 .38 .56 1.05 .14 .09 .36 1.05
D6S289 .114 .13 .46 .78 1.05 .10 .17 .60 1.05
D6S461 .005 .01 2.27 1.91 .018 (ALL) .20 .88 2.37 1.05
D6S276 .030 .22 1.29 1.68 1.05
D6S105 .006 .76 1.75 1.84 1.05 1.52 1.11 2.80 1.05
D6S265 .007 .33 .16 .50 1.05 1.34 .00 1.17 1.05
TNFb !.001 1.05
TNFa !.001 .29 1.70 2.12 1.05 1.19 1.22 3.36 1.05
LTA NcoI !.001 .00 .00 .65 1.05 .00 .00 .94 1.05
TNFc !.001 1.05 1.05
LTA Asn26 !.001 .00 .03 .70 1.05 .00 .01 .96 1.05
TNFA–308 !.001 .00 .00 .50 1.05 .36 .19 .75 1.05
TNFA–238 !.001 .20 .01 .48 1.05 .01 .02 .59 1.05
TNFd !.001 1.05 1.05
TNFe .035 1.05 1.05
D6S291 .054 .08 .47 .62 1.05 .36 .48 1.07 1.05
D6S426 .046 .20 .00 .10 .006 (ALL) .40 .02 .46 .004 (ALL)
D6S271 .119 .07 .11 .58 1.05 .19 .35 1.46 1.05
D6S257 .046 .00 .56 .03 1.05 .00 .72 .21 1.05
NOTE.—Marker distances were calculated, in the families analyzed, by use of the MULTIMAP program
(Matise et al. 1994). Map distances (in Kosambi cM) are given in map order, from the telomeric end
(marker D6S309) of chromosome 6p.
a Obtained by use of the MAPMAKER/SIBS program.
b Obtained by use of the TDTLIKE program from the ANALYZE software package.
in the additional families. Nonparametric linkage anal-
ysis revealed strengthened linkage evidence and a peak
multipoint LOD score of 4.2 at marker D6S461 in the
total IBD cohort. The MLS curves for CD, UC, and the
ALL cohorts are presented in figure 3. The maximum
two-point LOD score of 3.36 was observed for the mi-
crosatellite TNFa in the ALL cohort.
On the basis of the strong functional evidence link-
ing the TNFA and LTA molecules to IBD pathogenesis
and on the basis of their location near the linkage
peak, these genes were chosen for further investiga-
tion. Five known single-nucleotide polymorphisms in
the TNFA and LTA genes (table 2) and the five TNF
microsatellites were therefore genotyped in the ex-
panded population of 428 ASPs. The combination of
the microsatellite alleles TNFa2b1c2d4e1 had been
observed at an increased frequency in CD, in a pre-
vious case-control study (Plevy et al. 1996). In our
extended cohort, this allele combination was present
in 8.1% of patients with CD, in 10.1% of patients
with UC, and in 12.3% of unaffected parents (P 1
). Allele 2 of the “244” TNFA promoter poly-.10
morphism (Weissensteiner and Lanchbury 1997) was
observed in only three individuals. This finding sug-
gests that this polymorphism is not critically involved
in the etiology of IBD, and, therefore, it was excluded
from the linkage and association analysis. The asso-
ciation analysis of the single-nucleotide polymor-
phisms revealed no significant findings. All P values
were 1.25. The microsatellite markers were also an-
alyzed, by use of the TDT test, for evidence of as-
sociation. A single suggestive TDT result of P = .006
was observed for marker D6S426 ( ; 81 vs.2x = 10.3
45 transmissions) at the proximal flank of the linkage
curve in the basic cohort. This result was strengthened
by the addition of families in the extended population,
yielding a P value of .004 ( ; 97 vs. 56 trans-2x = 11.0
missions). The complete TDT results for all markers
are given in table 3.
Discussion
In this study, we have provided linkage evidence for
the existence of an IBD-susceptibility locus on chro-
mosome 6p. The peak multipoint LOD score of 4.2 sur-
passes the LOD-score criterion of 3.6 suggested for es-
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Figure 3 Multipoint MLS curves for markers typed in the peak
region of chromosome 6p. Markers were typed in the extended fam-
ily set of 428 ASPs. Multipoint analyses were performed with use
of the MAPMAKER/SIBS program. Results for CD (dashed line),
UC (thin unbroken line), and ALL (thick unbroken line) are shown.
Genetic distances between markers were estimated from the data set.
Marker positions are denoted by blackened diamonds.
tablishment of linkage in a complex genetic disorder
(Lander and Kruglyak 1995). The suggestive linkage
findings of other investigators provide further support
for this finding. From these data, we conclude that there
is a major disease-risk determinant for IBD in the region
surrounding the HLA complex on chromosome 6p. The
equal contribution of the subphenotypes of families with
CD, UC, and mixed CD/UC to the linkage result in the
ALL category (figs. 2 and 3) suggests that the underlying
gene may be important for both CD and UC. The over-
lap with the linkages for insulin-dependent diabetes mel-
litus, psoriasis, and other autoimmune disorders in the
HLA region may point to common factors that may play
a general role in the predisposition to dysregulated im-
mune responses (Nair et al. 1997; Becker et al. 1998;
Concannon et al. 1998). Alternatively, an IBD-specific
gene may eventually be identified in this region.
Substantial functional evidence and successful clinical
trials have implicated TNF-a in the pathogenesis of IBD
(Targan et al. 1997; Schreiber et al. 1999). In experi-
mental systems, variations in the TNFA promoter have
been associated with a differential capacity to produce
TNF-a in response to inflammatory stimuli (Kroeger et
al. 1997; Wilson et al. 1997). The 308 TNF-a pro-
moter polymorphism has been clearly linked to suscep-
tibility to malaria and meningococcal infection (Mc-
Guire et al. 1994; Nadel et al. 1996). The capacity to
produce TNF-a and IL-1b in lamina propria mononu-
clear cells has been used to predict relapse in CD (Schrei-
ber et al. 1999). On the basis of both the significant
functional evidence implicating TNF-a in the pathogen-
esis of IBD and the location at the center of our linkage
peak, this gene was selected for further investigation.
Previous studies have defined common variants in the
TNF genes. We investigated five known TNFA and LTA
polymorphisms that might have a functional relevance
for association to IBD. No association of the TNF single-
nucleotide polymorphisms or the microsatellites was de-
tected in the expanded cohort of 428 ASPs. We conclude
from these data that variations in TNF-a do not, there-
fore, predispose to IBD but, rather, likely act as an im-
portant secondary mediator in the inflammation process.
The use of TNF polymorphisms in the stratification or
reclassification of IBD does not, therefore, seem to be
warranted
There is a very high density of immunoregulatory
genes in the region implicated by the linkage. These
genes—in addition to TNF-a—include, among others,
the HLA antigens, members of the NFkB inflammatory
signal-transduction pathway, heat-shock proteins, anti-
gen-processing members of the ubiquitin complex, and
the complement family. Each of the members of these
gene families will have to be examined for genetic evi-
dence implicating it in the disease process. It is antici-
pated that this process will be extremely difficult because
of the exceptionally high density of immunoregulatory
genes in this genomic area.
Interestingly, a positive TDT association of P = .004
is observed for the anonymous microsatellite marker
D6S426, which is located at the proximal boundary of
the linkage region. The corresponding two-point LOD
score at this location is .46 in the total population with
IBD. Given the multiple association tests performed in
this study (table 3), this result may represent a false-
positive finding and, thus, should not be overinterpreted.
Alternatively, this result may point to a disease-gene lo-
cation on the proximal flank of the linkage peak. This
would correspond to a more proximal linkage-peak lo-
cation, which has been observed in other studies (Sil-
verberg et al. 1999). A difference in location between
the linkage peak and the actual gene location would not
be unexpected in a complex disorder (Kruglyak and
Lander 1996).
In summary, we have presented firm linkage evidence
for the existence of an IBD-susceptibility gene in the
HLA region. TNF-a, although clearly an important in-
flammatory mediator in IBD, does not appear to play
an important role in the genetic predisposition to the
disease. The single point association at D6S426 warrants
further investigation.
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